"e-Med - Demonstrationen zur Individualisierten Medizin" HER2-Low

About 70-80% of primary breast tumors show low or no detectable expression of HER2, however, other members of the ERBB family of receptor tyrosine kinases (RTK), EGFR and ERBB3, are frequently produced as potent drivers of tumor progression and of metastasis. The HER2Low consortium will therefore address the clinically relevant question, how to optimize treatment of breast cancer patients expressing HER2 at low to moderate levels.

Projektbeginn: 01.03.2015
Projektende: 28.02.2018

Timmer J.

Albert-Ludwigs-Universität Freiburg
Physikalisches Institut
Dynamische Prozesse in den Lebenswissenschaften
Hermann - Herder Str. 3
79104 Freiburg

Telefon: +49/761/203-5829
Fax: +49/761/203-8541
Email: jeti@fdm.uni-freiburg.de
http://webber.physik.uni-freiburg.de/~jeti/

• BMBF, BMBF